Patent 9896506 was granted and assigned to Genentech on February, 2018 by the United States Patent and Trademark Office.
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals, including immunoconjugates comprising anti-CD79b cysteine-engineered antibody huMA79b.v28, and to methods of using those compositions of matter for the same.